BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19557131)

  • 21. Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug oseltamivir (Tamiflu®) and loss of nutrient removal performance.
    Slater FR; Singer AC; Turner S; Barr JJ; Bond PL
    FEMS Microbiol Lett; 2011 Feb; 315(1):17-22. PubMed ID: 21133989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathobiology and virus shedding of low-pathogenic avian influenza virus (A/H1N1) infection in mallards exposed to oseltamivir.
    Bröjer C; Järhult JD; Muradrasoli S; Söderström H; Olsen B; Gavier-Widén D
    J Wildl Dis; 2013 Jan; 49(1):103-13. PubMed ID: 23307376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: a comparison with seasonal H1N1 with or without H275Y mutation.
    Kawai N; Ikematsu H; Iwaki N; Kondou K; Hirotsu N; Kawashima T; Maeda T; Tanaka O; Doniwa K; Iwakuni O; Egashira K; Yamaji K; Kashiwagi S
    J Infect Chemother; 2012 Apr; 18(2):180-6. PubMed ID: 22193710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments.
    Accinelli C; Saccà ML; Fick J; Mencarelli M; Lindberg R; Olsen B
    Chemosphere; 2010 May; 79(8):891-7. PubMed ID: 20226496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fate of new three anti-influenza drugs and one prodrug in the water environment.
    Azuma T; Ishida M; Hisamatsu K; Yunoki A; Otomo K; Kunitou M; Shimizu M; Hosomaru K; Mikata S; Mino Y
    Chemosphere; 2017 Feb; 169():550-557. PubMed ID: 27898328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Published sequences do not support transfer of oseltamivir resistance mutations from avian to human influenza A virus strains.
    Norberg P; Lindh M; Olofsson S
    BMC Infect Dis; 2015 Mar; 15():162. PubMed ID: 25887656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: kinetics, identification of the transformation products, and environmental occurrence.
    Gonçalves C; Pérez S; Osorio V; Petrovic M; Alpendurada MF; Barceló D
    Environ Sci Technol; 2011 May; 45(10):4307-14. PubMed ID: 21495632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using oseltamivir (Tamiflu) as a first line treatment for seasonal or pandemic flu.
    Greener M
    Nurs Times; 2009 Sep 1-7; 105(34):22. PubMed ID: 19788111
    [No Abstract]   [Full Text] [Related]  

  • 29. Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water.
    Gillman A; Nykvist M; Muradrasoli S; Söderström H; Wille M; Daggfeldt A; Bröjer C; Waldenström J; Olsen B; Järhult JD
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5196-202. PubMed ID: 26077257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivir.
    Gillman A
    Infect Ecol Epidemiol; 2016; 6():32870. PubMed ID: 27733236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the antiviral drug oseltamivir (Tamiflu) on the bacterial community structure of a surface water ecosystem analyzed using fluorescence in situ hybridization.
    Caracciolo AB; Grenni P; Saccà ML
    Bull Environ Contam Toxicol; 2010 Nov; 85(5):443-6. PubMed ID: 20957346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influenza A/H4N2 mallard infection experiments further indicate zanamivir as less prone to induce environmental resistance development than oseltamivir.
    Tepper V; Nykvist M; Gillman A; Skog E; Wille M; Lindström HS; Tang C; Lindberg RH; Lundkvist Å; Järhult JD
    J Gen Virol; 2020 Aug; 101(8):816-824. PubMed ID: 31855133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolation of oseltamivir-resistant influenza A/H1N1 virus of different origins in Yokohama City, Japan, during the 2007-2008 influenza season.
    Kawakami C; Obuchi M; Saikusa M; Noguchi Y; Ujike M; Odagiri T; Iwata M; Toyozawa T; Tashiro M
    Jpn J Infect Dis; 2009 Jan; 62(1):83-6. PubMed ID: 19168972
    [No Abstract]   [Full Text] [Related]  

  • 34. Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineages.
    Janies DA; Voronkin IO; Studer J; Hardman J; Alexandrov BB; Treseder TW; Valson C
    Int J Health Geogr; 2010 Feb; 9():13. PubMed ID: 20181276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of electrolysis for inactivation of an antiviral drug that is one of possible selection pressure to drug-resistant influenza viruses.
    Kobayashi T; Hirose J; Wu H; Sano K; Katsumata T; Tsujibo H; Nakano T
    J Virol Methods; 2013 Dec; 194(1-2):154-60. PubMed ID: 23994466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tamiflu survives sewage treatment.
    Renner R
    Environ Sci Technol; 2007 Nov; 41(22):7591. PubMed ID: 18075061
    [No Abstract]   [Full Text] [Related]  

  • 37. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
    Matsuzaki Y; Mizuta K; Aoki Y; Suto A; Abiko C; Sanjoh K; Sugawara K; Takashita E; Itagaki T; Katsushima Y; Ujike M; Obuchi M; Odagiri T; Tashiro M
    Virol J; 2010 Mar; 7():53. PubMed ID: 20202225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.
    Baranovich T; Saito R; Suzuki Y; Zaraket H; Dapat C; Caperig-Dapat I; Oguma T; Shabana II; Saito T; Suzuki H;
    J Clin Virol; 2010 Jan; 47(1):23-8. PubMed ID: 19962344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.
    Toovey S; Rayner C; Prinssen E; Chu T; Donner B; Thakrar B; Dutkowski R; Hoffmann G; Breidenbach A; Lindemann L; Carey E; Boak L; Gieschke R; Sacks S; Solsky J; Small I; Reddy D
    Drug Saf; 2008; 31(12):1097-114. PubMed ID: 19026027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.